ADVFN US – Market Content Editor
-

Rising Oil and Surging Yields Drive Wall Street to a Third Straight Loss
US stocks fell for a third consecutive session on Wednesday, September 9, 2026, as a fresh surge in oil prices and a jump in Treasury yields kept investors on the defensive. Crude oil pushed past $100 a barrel amid renewed US-Iran tensions, stoking worries about inflation and corporate profit margins, while a climb in borrowing…
-

Markets in Motion: Rising inflation reshapes Fed outlook as Q4 approaches
Bruce Campbell examines rising inflation, Fed rate expectations, sector rotation and what the U.S. presidential cycle could signal for Q4.
-

American Gold & Copper Signs $10 Million Rimrock Copper-Gold Project Acquisition in Nevada
American Gold & Copper Inc. (USOTC:AGCI) has signed a definitive $10 million acquisition agreement for the Rimrock Copper-Gold Project in Nevada, adding 77 mining claims covering approximately 1,540 acres and committing about $1.5 million to an initial 18-month exploration programme. Key Investor Takeaways Why AGCI Stock Is in Focus American Gold & Copper has moved…
-

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor Takeaways Why RZLT Stock Is in Focus Rezolute’s regulatory discussions…
-

SunHydrogen Commercialization Path Targets Repeatable Full-Size Hydrogen Module Performance
SunHydrogen (USOTC:HYSR) outlined its commercialization path for its renewable hydrogen technology, setting year-end 2026 objectives around repeatable full-size module performance, integrated-system reliability and manufacturing consistency while confirming that it has not yet secured a customer or offtake agreement. Key Investor Takeaways Why HYSR Stock Is in Focus SunHydrogen provided new detail on the engineering and…
-

TurboGen Signs Business Development Agreement With Eric Adams to Expand Global Market Access
TurboGen Ltd. (NASDAQ:TRBG) has signed a strategic business consulting and development agreement with a group including former New York City Mayor Eric Adams, who will join the company’s Advisory Board and support efforts to expand commercial relationships in the U.S. and international markets. Key Investor Takeaways Why TRBG Stock Is in Focus TurboGen has brought…
-

America’s Car-Mart Revenue Falls 57% as Capital Constraints Drive 82% Drop in Retail Sales
America’s Car-Mart (NASDAQ:CRMT) reported a 57.3% decline in first-quarter fiscal 2027 revenue to $145.8 million as capital constraints sharply reduced inventory and vehicle sales, while weaker credit performance and an ongoing review of financing and strategic alternatives add to near-term uncertainty. Key Investor Takeaways Why CRMT Stock Is in Focus America’s Car-Mart’s operating contraction accelerated…
-

Nanox Q2 Revenue Rises 37% as $40.7 Million Impairment Drives Wider GAAP Loss
Nanox (NASDAQ:NNOX) reported a 37% increase in second-quarter 2026 revenue to $4.2 million, but its GAAP net loss widened to $55.5 million following a $40.7 million impairment charge, while cash declined and the company said it intends to continue raising funds. Key Investor Takeaways Why NNOX Stock Is in Focus Nanox’s Q2 revenue growth was…
-

Mint Signs MENA Education Robotics MOU Targeting 3,000-Unit Deployment
Mint Incorporation Limited (NASDAQ:MIMI) said its majority-owned joint venture Rice Robotics AGI has signed a non-binding MENA education robotics MOU with Edvance Innovation, outlining a commercial goal of deploying 3,000 educational robotics units over 36 months and targeting an initial 50-unit purchase order by November 30, 2026. Key Investor Takeaways Why MIMI Stock Is in…
-

Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027
Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that could lead to Phase 3 participant dosing in 2027. Key Investor Takeaways Why IRD Stock Is in Focus The Phase 1/2 data provide the first low-dose…